Comprehensive Screening for Women at High Genetic Risk for Developing Breast Cancer

This study has been completed.
Sponsor:
Collaborators:
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00255060
First received: November 15, 2005
Last updated: July 16, 2010
Last verified: July 2010
  Purpose

To screen women who are high risk for breast cancer with breast MRI, mammogram and random periareolar fine needle aspiration.


Condition
Breast Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Comprehensive Screening for Women at High Genetic Risk for Developing Breast Cancer

Resource links provided by NLM:


Further study details as provided by Stanford University:

Estimated Enrollment: 100
Study Start Date: November 2001
Study Completion Date: June 2007
Primary Completion Date: July 2006 (Final data collection date for primary outcome measure)
Detailed Description:

General Purpose: The purpose of our protocol is develop a comprehensive screening protocol for women at high risk for developing breast cancer in the hopes of detecting breast cancer or it's precursor lesions at the earliest possible stage and reducing breast cancer mortality.

The following are our specific goals in this endeavor;

  1. To assess the sensitivity and specificity of MRI in breast cancer detection in women at high risk compared to mammography
  2. To assess the ability of random periareolar fine needle aspiration to detect abnormal ductal cells and to correlate these results with MRI and mammogram findings
  3. To assess appropriate screening intervals for BRCA1/2 mutation carriers and women with a >10% risk of developing breast cancer in ten years The following aims will be outlined in detail under methodology.
  Eligibility

Ages Eligible for Study:   25 Years to 65 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Women with high risk of breast cancer

Criteria

Inclusion Criteria:Subjects must be female, between the ages of 25 and 65, or ten years younger than the youngest breast cancer diagnosed in the family, or have no mutation identified but have a greater than 10% risk of developing breast cancer in ten years (based on the Claus Model).

May have had previous breast or ovarian cancer, but must be at least one year out from treatment of a Stage 1 or early 2 cancer.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00255060

Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: James M Ford Stanford University
  More Information

No publications provided

Responsible Party: James M Ford, Stanford University School of Medicine
ClinicalTrials.gov Identifier: NCT00255060     History of Changes
Other Study ID Numbers: BRSNSTU0002, 77716, BRSNSTU0002
Study First Received: November 15, 2005
Last Updated: July 16, 2010
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on July 22, 2014